Although there are currently no mAbs targeting FGL1, many mAbs targeting LAG-3 are undergoing clinical trials, including relatlimab (first LAG-3 mAb), and show good potential in tumor immunotherapy60. This evidence concerns the gene FGL1 and neoplasm.